Pharmadrug Inc.
PHRX
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -95.45% | -95.02% | -63.91% | 47.44% | 30.11% |
| Depreciation & Amortization | -4.50% | 26.57% | 90.16% | 7,933.33% | 6,400.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.01% | -88.62% | -57.05% | 37.30% | 12.24% |
| Operating Income | 85.01% | 88.62% | 57.05% | -37.30% | -12.24% |
| Income Before Tax | 97.34% | 96.99% | 93.86% | -1,065.21% | -1,044.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 97.14% | 96.76% | 93.40% | -894.24% | -1,153.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.79% | 1.03% | 121.16% | -- | -- |
| Net Income | 97.91% | 97.52% | 94.39% | -1,032.89% | -659.92% |
| EBIT | 85.01% | 88.62% | 57.05% | -37.30% | -12.24% |
| EBITDA | 88.36% | 91.53% | 60.25% | -32.25% | -9.57% |
| EPS Basic | 98.56% | 98.25% | 95.81% | -697.53% | -435.63% |
| Normalized Basic EPS | 87.00% | 87.30% | 72.87% | -22.86% | -26.58% |
| EPS Diluted | 98.56% | 98.25% | 95.83% | -733.55% | -451.25% |
| Normalized Diluted EPS | 87.00% | 87.30% | 72.87% | -22.86% | -26.58% |
| Average Basic Shares Outstanding | 32.47% | 53.89% | 78.24% | 84.18% | 57.94% |
| Average Diluted Shares Outstanding | 32.47% | 53.89% | 78.24% | 84.18% | 57.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |